Chemometec — Februar 2024
-
@michou. Evt. børsmedd. vedr. Xm40? Jeg forventer ikke voldsom megen information løbende
-
Undskyld, skulle være vedr. XM30
-
Det lader til at det første Fase 3 forsøg med Car-T behandling af faste tumorer er blevet "fasttracked" af FDA. Chemm mener at eksisterende celletæller samt Xcyto 5 er ideelle til denne type behandling. Se deres opslag på linkedin her : https://www.linkedin.com/feed/update/urn:li:activity:7166739097409994752/?origin=NETWORK_CONVERSATIONS&midToken=AQH2eJ6K7QgO3A&midSig=2mJdxS5wwoDr81&trk=eml-email_network_conversations_01-network~post~cta-0-read~more&trkEmail=eml-email_network_conversations_01-ne
-
Iovance has on-boarded 30 designated centers ready to treat patients at the drug’s launch, and the company is on track to have more than 50 centers in about 100 days, Iovance’s commercial chief, Jim Ziegler, said on the call. https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor
-
-
-
Shortpositioner på danske aktier https://oam.finanstilsynet.dk/#!/stats-and-extracts-short-net-positions
-
Det lysner
500+ er pludselig ikke så langt væk mere…Lad os håbe
det fortsætter
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind